← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT07296653

Prolotherapy in Acupoints in Chronic Non-specific Low Back Pain (cLBP)

Trial Parameters

Condition Chronic Non-specific Low Back Pain
Sponsor National and Kapodistrian University of Athens
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 60
Sex ALL
Min Age 35 Years
Max Age N/A
Start Date 2025-12-01
Completion 2026-12
Interventions
Dextrose 15% and lidocaine 1% infiltrationLidocaine 1% infiltration

Brief Summary

Chronic non-specific low back pain (CNSLBP) is among the most prevalent causes of disability on the planet, which often proves to be refractory to conventional pharmacological, interventional, and rehabilitation approaches. Although acupuncture has also shown analgesic effectiveness, its variability and reliance on practitioner skill limit its universal introduction into Western medical practice. Prolotherapy, an emerging regenerative injection treatment with hypertonic dextrose solutions, has been of potential benefit in managing musculoskeletal pain by triggering tissue repair and controlling neurogenic inflammation. Interestingly, several acupuncture points correspond to neuroanatomically relevant sites. This single-blind randomized controlled trial aims to ascertain whether combinational prolotherapy with dextrose 15% and lidocaine 1% is superior to lidocaine 1% in patients with CNSLBP. Sixty patients will be allocated randomly into two equal-sized groups and receive a maximum of 15 ultrasound-guided injections into standardized acupoints of the lumbar area (BL23, BL25, BL31, BL54, GV3, GV4, and Ashi points) during three treatment sessions. Outcomes will be evaluated using the Numeric Rating Scale (NRS), the Oswestry Disability Index (ODI), the TUG (Timed Up and Go) test, the BPI (Brief Pain Inventory) scale, the Rolland-Morris Low Back Pain Disability Questionnaire and the Global Impression of Pain Questionnaire at baseline, and at 15, 30, and 90 days post-treatment. Outcomes should clarify whether dextrose-enhanced prolotherapy provides improved analgesia and functional return in comparison with local anesthetic injection alone. This study can present an uncomplicated, low-cost, and integrative regimen for CNSLBP with significant clinical and socioeconomic implications.

Eligibility Criteria

Inclusion Criteria: * Body Mass Index (BMI) up to 45 kg/m2 * Diagnoses corresponding to \>1 of the following ICD-10 (International Classification of Diseases): 1. M51.3 Degeneration of intervertebral discs 2. M54.5 Low back pain 3. M54.8 Other forms of back pain 4. M54.9 Various forms of back pain 5. S33.5 Sprain of the lumbar spine 6. S33.6 Sprain of sacroiliac joint 7. S33.7 Sprain of other and various parts of lumbar spine and pelvis * Diagnosis of chronic nonspecific low back pain: Chronic nonspecific low back pain refers to pain in the lower back with or without radiation to the lower extremities, lasting for more than 3 months and not attributable to a specific anatomical structure or pathology on imaging, for example generalized degenerative changes, but no pathological findings (such as spinal stenosis or disorders of the sagittal/coronal architecture or intervertebral foramen stenosis) with neurological deficits and no symptoms specific to the predominant pathology. * Numerica

Related Trials